Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.58)
# 763
Out of 5,182 analysts
81
Total ratings
54.93%
Success rate
22.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $24.53 | +38.61% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $52.06 | +42.14% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $430.14 | +23.22% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $13.75 | -12.73% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $302.11 | +70.48% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.02 | -60.16% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $40.89 | +10.05% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.86 | +35.44% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $3.06 | +63.40% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $53.85 | -35.00% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $516.69 | -30.33% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $4.74 | -57.81% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $2.74 | +812.41% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.96 | +402.87% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $37.11 | -35.33% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $16.76 | +79.00% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.15 | +140.96% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $24.53
Upside: +38.61%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $52.06
Upside: +42.14%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $430.14
Upside: +23.22%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $13.75
Upside: -12.73%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $302.11
Upside: +70.48%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.02
Upside: -60.16%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $40.89
Upside: +10.05%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.86
Upside: +35.44%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $3.06
Upside: +63.40%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $53.85
Upside: -35.00%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $516.69
Upside: -30.33%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $4.74
Upside: -57.81%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $2.74
Upside: +812.41%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.96
Upside: +402.87%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $37.11
Upside: -35.33%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $16.76
Upside: +79.00%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.15
Upside: +140.96%